Addendum

Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28

Status
Status: Commission completed
Project no.
A25-84
Last updated

Report documents

  1. Addendum

    Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28

    published on
    Document type
    PDF document, 442 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-84_en

Dossier assessment

Indication:

Pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments

Additional information

Federal Joint Committee (G-BA)

07-08-2025 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A25-84
Commission
Commission awarded on 24.06.2025 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A25-84_en

Connected Projects

  1. Dossier assessment

    Sipavibart (pre-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-28
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form